Restart Life Sciences Beheer

Beheer criteriumcontroles 1/4

De CEO Restart Life Sciences is Steve Loutskou, benoemd in Oct2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 3.11% van de aandelen van het bedrijf, ter waarde CA$ 36.92K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 3.3 jaar.

Belangrijke informatie

Steve Loutskou

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	3.1%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

This Is Why Nova Mentis Life Science Corp.'s (CSE:NOVA) CEO Compensation Looks Appropriate

Dec 09

We Think Nova Mentis Life Science (CSE:NOVA) Can Afford To Drive Business Growth

Dec 07

CEO

Steve Loutskou

less than a year

Tenure

Mr. Steve Loutskou is President and Chief Executive Officer of Restart Life Sciences Corp. (formerly known as Nova Mentis Life Science Corp.) from October 22, 2024. He is Director of Restart Life Sciences...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rebecca Hudson	Chief Financial Officer	2.9yrs	CA$72.00k	1.17% CA$ 13.9k
Derek Lloyd Ivany	Executive Chairman	1.8yrs	geen gegevens	2.4% CA$ 28.5k
Steve Loutskou	President	less than a year	geen gegevens	3.11% CA$ 36.9k
Aylia Mohammadi	President & Chief Scientific Officer of Nova Mentis Biotech Corp.	no data	CA$36.00k	geen gegevens
Kelly Pladson	Corporate Secretary	no data	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

41yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HEAL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Derek Lloyd Ivany	Executive Chairman	1.8yrs	geen gegevens	2.4% CA$ 28.5k
Steve Loutskou	President	less than a year	geen gegevens	3.11% CA$ 36.9k
Marvin Hausman	Chairman of Scientific Advisory Board	3.9yrs	geen gegevens	geen gegevens
Georg Hochwimmer	Director	less than a year	geen gegevens	geen gegevens
Kyle Ambert	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Julia Perederiy	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
Gary Harlem	Member of Scientific Advisory Board	3.8yrs	geen gegevens	geen gegevens
John Molinaro	Member of Scientific Advisory Board	2.8yrs	geen gegevens	geen gegevens
Viviana Trezza	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HEAL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Restart Life Sciences Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Nova Mentis Life Science Corp Announces Chief Executive Officer Changes

Nova Mentis Life Science Corp Announces Chief Executive Officer Changes

Nova Mentis Life Science Corp., Annual General Meeting, Dec 03, 2024

Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director

Nova Mentis Life Science Corp., Annual General Meeting, Dec 29, 2023

Nova Mentis Life Science Corp. Announces Board Changes

Recent updates

Nova Mentis Life Science Corp Announces Chief Executive Officer Changes

Nova Mentis Life Science Corp Announces Chief Executive Officer Changes

Nova Mentis Life Science Corp., Annual General Meeting, Dec 03, 2024

Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director

Nova Mentis Life Science Corp., Annual General Meeting, Dec 29, 2023

Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial

Nova Mentis Life Science Corp. Announces Board Changes

Nova Mentis Receives Health Canada Approval for First-Of-its-Kind Psilocybin Clinical Trial

This Is Why Nova Mentis Life Science Corp.'s (CSE:NOVA) CEO Compensation Looks Appropriate

Less than half of directors are independent

Nova Mentis Life Science Corp., Annual General Meeting, Dec 15, 2022

Nova Mentis Life Science Corp. Produces 1.5 mg Psilocybin Microdose Capsules

Nova Mentis Life Science Corp. Completes Production of Psilocybin Microdose Capsules

Nova Mentis Life Science Corp. Receives Controlled Substances Export Approval From The U.S. DEA for the Proprietary Psilocybin Drug NM 1001

Nova Mentis Life Science Corp. Appoints John Molinaro to its Scientific Advisory Board

Nova Mentis Life Science Corp Receives Approved Health Canada Importation Permit

Full year 2021 earnings released: CA$0.024 loss per share (vs CA$0.45 loss in FY 2020)

Less than half of directors are independent

Nova Mentis to Produce Psilocybin Capsules for Phase 2A Clinical Study

Nova Mentis Completes Oral Microdose Psilocybin Preclinical Study

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Nova Mentis Life Science Corp. Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment

First half 2021 earnings released: CA$0.009 loss per share (vs CA$0.20 loss in 1H 2020)

Nova Mentis Life Science Corp. Receives Canadian Approval for its North American Autism Clinical Study

Nova Mentis Life Science Corp. Launches Autism Clinical Study

Nova Mentis Life Science Corp. Announces the Launch of Its Us-Based Observational Study Nm- 101

Nova Mentis Life Science Corp. Receives Approval for Its First Clinical Program in Autism Spectrum Disorder

Nova Mentis Life Science Corp. Expands Pre-Clinical Development Pipeline and Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug

Nova Mentis Life Science Corp. Appoints Gary R. Harlem to its Scientific Advisory Board

Nova Mentis Life Science Corp. Approves for Shipment to Italy

Nova Launches Preclinical Autism Spectrum Disorder Therapeutic Study

Nova Mentis Life Science Corp. Appoints Julia V. Perederiy, Phd to Its Scientific Advisory Board

Nova Mentis Life Science Corp Appoints Kyle H. Ambert as Scientific Advisory Board

Nova Mentis Life Science Corp. Announces That It Has Added Two Additional Psychedelic Compounds to Its Drug Portfolio

We Think Nova Mentis Life Science (CSE:NOVA) Can Afford To Drive Business Growth

Nova Mentis Life Science Corp. Appoints Marvin S. Hausman as Chairman of Scientific Advisory Board

New 90-day high: CA$0.27

Nova Mentis Life Science Corp. Appoints Marvin S. Hausman MD as Chairman of Nova’S Scientific Advisory Board and Amalco’s Chief Medical Officer

New 90-day high: CA$0.22

New 90-day high: CA$0.21

Nova Mentis Life Science Corp. Announces Executive Changes

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd